Metformin is an oral insulin sensitizer that, when added to the GnRH antagonist protocol, increases the sensitivity of the ovaries to gonadotropins and reduces the risk of OHSS [8]. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.